BridgeMD
Efficacy of Tuvusertib in Recurrent IDH mutant Astrocytoma with ATRX mutation, a phase II prospective trial.
EU CTIS ID: 2025-521843-19-00
What this study is testing
The primary objective of this study is to evaluate efficacy of tuvusertib monotherapy in patients with first recurrence of IDH1/2-mutated, ATRX-mutated and p53-mutated astrocytoma by means of progression-free survival (PFS) locally assessed by investigators by magnetic resonance imaging (MRI) following RANO criteria version 2.0
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Written informed consent approved by the Independent Ethics Committee (IEC), prior to the performance of any trial activities.
- Contraceptive use by males or females will be consistent with local regulations on contraception methods for those participating in clinical studies. Male participants: Agree to the following during the study intervention period and for at least 3 months after the last dose of tuvusertib: a. Refrain from donating sperm. PLUS, either: b. Abstain from any activity that allows for exposure to ejaculate. OR c. Use a male condom: i. When having sexual intercourse with a woman of childbearing potential (WOCBP), and advise her to use a highly effective contraceptive method with a failure rate of < 1% per year, as described in Appendix 4 of study protocol, since a condom may break or leak. ii. Male participants must use a condom with pregnant female partners during the study. Female participants: Are not pregnant or breastfeeding, and at least 1 of the following conditions applies: a. Not a women of childbearing potential (WOCBP) OR b. If a WOCBP, use a highly effective contraceptive method (i.e., with a failure rate of < 1% per year), preferably with low user dependency, as described in Appendix 4 of study protocol for the following time periods: i. Before the first dose of tuvusertib, if using hormonal contraception has completed at least one 4-week cycle of an oral contraception pill and either had or has begun her menses. ii. During the intervention period iii. After the study intervention period for at least 6 months after the last dose of tuvusertib and agree not to donate eggs (ova, oocytes) for reproduction during this period. c. If a WOCBP, have a negative serum pregnancy test, as required by local regulations, within 72 hours before the first dose of tuvusertib.
- Patients able to take oral medications.
- Willingness and ability of patients to comply with the protocol for the duration of the study including undergoing treatment as well as availability for scheduled visits and examinations including follow-up.
- Patients, males and females, ≥ 18 years of age at the time of signing the informed consent.
- Patients with Karnofsky performance status (KPS) index > 60%
You likely can't join if
- Patients with radiographic recurrence without contrast enhancement by MRI.
- Active and/or uncontrolled infection. The following exceptions apply: a. Participants with HIV infection are eligible if they are on effective antiretroviral therapy with undetectable viral load within 6 months, provided there is no expected drug-drug interaction b. Participants with evidence of chronic HBV infection are eligible if the HBV viral load is undetectable on suppressive therapy (if indicated), and if they have ALT, AST, and total bilirubin levels < ULN, and provided there is no expected drug-drug interaction c. Participants with a history of HCV infection are eligible if they have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load, and if they have ALT, AST, and total bilirubin levels < ULN.
- Treatment with live or live attenuated vaccine within 30 days of dosing.
- Known hypersensitivity to the components of tuvusertib.
- Major surgery (as deemed by the Investigator) for any reason, except diagnostic biopsy, within 4 weeks of the study intervention and/or if the patient has not fully recovered from the surgery within 4 weeks of the study intervention.
- Leptomeningeal dissemination and/or extracranial metastases.
See the full eligibility criteria
Who can join
- Written informed consent approved by the Independent Ethics Committee (IEC), prior to the performance of any trial activities.
- Contraceptive use by males or females will be consistent with local regulations on contraception methods for those participating in clinical studies. Male participants: Agree to the following during the study intervention period and for at least 3 months after the last dose of tuvusertib: a. Refrain from donating sperm. PLUS, either: b. Abstain from any activity that allows for exposure to ejaculate. OR c. Use a male condom: i. When having sexual intercourse with a woman of childbearing potential (WOCBP), and advise her to use a highly effective contraceptive method with a failure rate of < 1% per year, as described in Appendix 4 of study protocol, since a condom may break or leak. ii. Male participants must use a condom with pregnant female partners during the study. Female participants: Are not pregnant or breastfeeding, and at least 1 of the following conditions applies: a. Not a women of childbearing potential (WOCBP) OR b. If a WOCBP, use a highly effective contraceptive method (i.e., with a failure rate of < 1% per year), preferably with low user dependency, as described in Appendix 4 of study protocol for the following time periods: i. Before the first dose of tuvusertib, if using hormonal contraception has completed at least one 4-week cycle of an oral contraception pill and either had or has begun her menses. ii. During the intervention period iii. After the study intervention period for at least 6 months after the last dose of tuvusertib and agree not to donate eggs (ova, oocytes) for reproduction during this period. c. If a WOCBP, have a negative serum pregnancy test, as required by local regulations, within 72 hours before the first dose of tuvusertib.
- Patients able to take oral medications.
- Willingness and ability of patients to comply with the protocol for the duration of the study including undergoing treatment as well as availability for scheduled visits and examinations including follow-up.
- Patients, males and females, ≥ 18 years of age at the time of signing the informed consent.
- Patients with Karnofsky performance status (KPS) index > 60%
- Diagnosis of Grade 2-4 astrocytoma, IDH-mutated according to the 2021 WHO classification.
- Patients must have confirmed ATRX mutation (IHC or NGS sequencing) and p53 mutation (NGS sequencing). Evaluation of CDKN2A also is required by FISH or NGS.
- Patients must have progressive disease and evaluable disease according to RANO 2.0 criteria. All patients should have MRI contrast enhancement disease.
- Patients must have undergone previous standard treatment with radiotherapy and chemotherapy (procarbazine, lomustine and vincristine [PCV] or temozolomide [TMZ]).
- Stable corticosteroid doses during the 2 weeks previous to the first dose of tuvusertib, maximum dose of dexamethasone 4 mg/day or equivalent.
- Adequate hematologic, hepatic and renal function as follows: a. Platelet count ≥ 100,000/mm 3 , b. Hemoglobin ≥ 9.0 g/dL, c. Absolute neutrophil count ≥ 1,500/μL with no growth factor treatment within the last 14 days, d. Total bilirubin level ≤ 1.5 × upper limit of normal (ULN) (if Gilbert’s Syndrome may have total bilirubin > 1.5 × ULN), e. Aspartate aminotransferase (AST) level ≤ 3 × ULN, and an alanine aminotransferase (ALT) level ≤ 3 × ULN. f. Serum creatinine ≤ 1.5 × ULN. If serum creatinine is > 1.5 × ULN, creatinine clearance needs to be ≥ 50 mL/min, as estimated by Cockroft-Gault formula: Males: Creatinine CL (mL/min) = Weight (kg) × (140 – Age) 72 x serum creatinine (mg/dL) - Females: Creatinine CL (mL/min) = Weight (kg) × (140 – Age) ×0.85 72 x serum creatinine (mg/dL)
What rules you out
- Patients with radiographic recurrence without contrast enhancement by MRI.
- Active and/or uncontrolled infection. The following exceptions apply: a. Participants with HIV infection are eligible if they are on effective antiretroviral therapy with undetectable viral load within 6 months, provided there is no expected drug-drug interaction b. Participants with evidence of chronic HBV infection are eligible if the HBV viral load is undetectable on suppressive therapy (if indicated), and if they have ALT, AST, and total bilirubin levels < ULN, and provided there is no expected drug-drug interaction c. Participants with a history of HCV infection are eligible if they have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load, and if they have ALT, AST, and total bilirubin levels < ULN.
- Treatment with live or live attenuated vaccine within 30 days of dosing.
- Known hypersensitivity to the components of tuvusertib.
- Major surgery (as deemed by the Investigator) for any reason, except diagnostic biopsy, within 4 weeks of the study intervention and/or if the patient has not fully recovered from the surgery within 4 weeks of the study intervention.
- Leptomeningeal dissemination and/or extracranial metastases.
- Patients who received more than 1 previous systemic line of treatment for astrocytoma.
- Patients who received previous treatment with bevacizumab.
- Persistence of AEs related to any prior treatments that have not recovered to Grade ≤ 1 unless AEs are clinically nonsignificant (e.g. alopecia) and/or stable on supportive therapy in the opinion of the Investigator.
- No prior ATR inhibitor and/or CHK1 inhibitor.
- Concurrent treatment with a non permitted drug/intervention: a. Prohibited concomitant medication, as listed in Section 7.8. b. Anticancer treatment within 30 days or 5 half-lives, whichever is shorter, prior to Day 1 of study intervention (6 weeks for nitrosoureas or mitomycin C). c. Prior palliative radiotherapy to metastatic lesion(s) is permitted provided it was completed ≥ 12 weeks prior to study intervention administration and participants have recovered from all related radiotherapy toxicities to Grade ≤ 1. d. Another investigational drug within 30 days or 5 half-lives, whichever is shorter, prior to start of tuvusertib administration. e. Increasing dose of corticoids. f. Received hematopoietic growth factor (e.g., granulocyte colony-stimulating factor, erythropoietin) within 14 days prior to the first dose of tuvusertib.
- Significant cardiac disease: a. Unstable angina, myocardial infarction, congestive heart failure ≥ stage II) or a coronary revascularization procedure within 180 days of study entry. b. Calculated QTc average (using the Fridericia correction calculation) of > 450 msec for males and > 470 msec for females.
- Uncontrolled hypertension.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.